Secondary progressive MS (SPMS) can affect both physical health and cognitive abilities. According to a review published in 2019, small studies have found that roughly 55 to 80 percent of people ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have ...

"With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Shares of Tiziana Life Sciences climbed after the company said it has expanded a Phase 2 clinical trial that is underway of its treatment for multiple sclerosis, an autoimmune condition that affects ...

IMUX stock's drop appears to be an overreaction, given positive disability progression data and clean safety profile. Click ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Enrollment is now complete in two Phase 3 clinical trials testing vidofludimus calcium in adults with relapsing forms of ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...